Jubilant Ingrevia Limited has successfully completed its acquisition of 100% equity stake in Remidex Pharma Private Limited, marking a significant milestone in the company's strategic expansion within the pharmaceutical sector. The transaction was completed on March 30, 2026 at 6:05 pm IST, following the Share Purchase Agreement that was initially announced on March 13, 2026.

Transaction Completion Details

The acquisition represents the culmination of a strategic process that began with the Share Purchase Agreement entered into between Jubilant Ingrevia and Remidex Pharma Private Limited. The company has fulfilled all regulatory disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance and Disclosure

Jubilant Ingrevia has maintained full compliance with regulatory requirements throughout the acquisition process. The company initially disclosed the transaction details on March 13, 2026, providing all necessary information pursuant to Regulation 30 read with SEBI Master Circular No: HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.

The completion of this acquisition has been formally communicated to both BSE Limited and National Stock Exchange of India Limited, ensuring full transparency with all stakeholders. The company has also updated its website with relevant documentation related to this transaction.

Strategic Implications

This acquisition strengthens Jubilant Ingrevia's position in the pharmaceutical sector by bringing Remidex Pharma's capabilities and assets under its direct control. The 100% equity acquisition provides the company with complete operational control over Remidex Pharma's business operations and strategic direction.

The successful completion of this transaction demonstrates Jubilant Ingrevia's commitment to growth through strategic acquisitions and its ability to execute complex corporate transactions within established timelines. The acquisition aligns with the company's broader expansion strategy in the pharmaceutical and specialty chemicals sectors.

Jubilant Ingrevia Limited's promoter group entities have disclosed the creation of pledge on equity shares under SEBI Takeover Regulations. The disclosure, dated March 25, 2026, pertains to the pledging of shares by two family trusts associated with the company's promoter group.

Pledge Details

The pledge was created on March 23, 2026, involving trustee companies acting on behalf of two prominent family trusts. The transaction involved pledging equity shares to Bajaj Finance Limited as security for a loan availed by Jubilant Enpro Private Limited.

Family Trust Holdings and Pledge Creation

Both family trusts created identical pledges as part of this transaction. The Hari Shanker Bhartia Family Trust, represented by HSB Trustee Company Private Limited and HS Trustee Company Private Limited, pledged 2,00,000 shares. Similarly, the Shyam Sunder Bhartia Family Trust, represented by SPB Trustee Company Private Limited and SS Trustee Company Private Limited, also pledged 2,00,000 shares.

Promoter Group Structure

The disclosure also provides details of the complete promoter group structure of Jubilant Ingrevia Limited. The promoter group includes individual promoters and corporate entities with varying shareholdings in the company.

Individual Promoters:

• Mr. Privavrat Bhartia holds 13,98,010 shares (0.88%)
• Mr. Hari Shanker Bhartia holds 3,60,885 shares (0.23%)
• Mr. Shamit Bhartia holds 1,29,245 shares (0.08%)
• Mrs. Kavita Bhartia holds 10,285 shares (0.01%)
• Mr. Shyam Sunder Bhartia holds 5,000 shares (0.00%)

Corporate Entities:

• MAV Management Advisors LLP: 50,11,400 shares (3.15%)
• Miller Holdings Pte Limited: 56,15,555 shares (3.53%)
• Jaytee Private Limited: 7,600 shares (0.00%)

Regulatory Compliance

The disclosure was made in compliance with Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was submitted to both NSE and BSE, where Jubilant Ingrevia's shares are listed. The disclosure was signed by Sandeep Kumar Dubey, Director (DIN: 10339310), on behalf of the promoter group entities.